Scott Gottlieb, MD, and Ted Okon, MBA, discuss controversies surrounding a proposed legislative amendment that would allow the government to negotiate drug prices with pharmaceutical companies.
Government intervention in drug pricing would impede fair market competition, remarks Mr Okon. Dr Gottlieb and Mr Okon further discuss how the government’s control of drug pricing may affect innovation. Together, they conclude that pricing controls may affect pharmaceutical companies’ decision making regarding drug contracting and pricing. As an example, Dr Gottlieb highlights the effects of the Medicaid “best price” system.
Dr Gottlieb explains the importance of a fair market and competitive pricing scheme and their effects on insurance companies, pharmacy benefit managers, and other stakeholders in healthcare, and suggests that these are potential market-based answers to the question of how to make healthcare more affordable.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces at AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More